Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Five-year research partnership targets breast cancer vaccine


News release, March 21 2017

Five-year research partnership targets breast cancer vaccine

Imagine if no one died from breast cancer…if we stopped it in its tracks, so it couldn’t spread and kill.

That’s the aim of a new five-year research partnership between Breast Cancer Foundation NZ and Ferrier Research Institute at Victoria University in Wellington.

The first project in the new BCFNZ Ferrier Breast Cancer Research Programme will see Ferrier’s team of world-leading carbohydrate chemists, headed by Professor Richard Furneaux, pouring its considerable skills into developing a “therapeutic vaccine” for breast cancer.

Unlike regular vaccines given to healthy people to prevent disease developing, a therapeutic vaccine will stimulate a patient’s own immune system to attack and destroy breast cancer cells. Excitingly, the first use of such a vaccine is likely to be in patients with currently incurable cancer that has spread beyond the breast, or in those whose tumours are resistant to existing treatments and likely to spread. (Almost all breast cancer deaths are the result of the cancer spreading; whereas cancer that’s confined to the breast can be treated successfully).

Breast Cancer Foundation NZ has pledged an initial $500,000 to the BCFNZ Ferrier Breast Cancer Research Programme, which will focus on bringing new drugs – starting with a therapeutic vaccine – to the clinical trial stage. The partnership will run for at least five years.

“We went looking for a research partner who would give us the best shot of moving toward our vision of zero deaths from breast cancer,” said Evangelia Henderson, chief executive at BCFNZ. “We were blown away by the calibre of the Ferrier team, the work they’d already done in the exciting field of immunotherapy and vaccines, and the strength of their international partnerships. It was a no-brainer for us.”

The Breast Cancer Foundation will, as usual, be relying on the generosity of its donors and corporate supporters to fund this new research partnership, and Evangelia Henderson is hopeful that the Foundation’s Pink Ribbon Breakfast fundraising campaign, held in May, will be a big boost to its funds available for research. “This is a great chance to get in on the ground floor of new drug development right here in New Zealand. There are no guarantees in research, and it’s always a long haul, but we feel that Ferrier is ideally placed to turn the vaccine vision into reality. We’ll be looking to raise funds to ensure their work is well resourced to go full speed ahead.”

Ferrier’s successful immunotherapy treatment platform has already led to the establishment of biotechnology company Avalia Immunotherapies, which aims to commercialise vaccine technology to help New Zealanders. Avalia’s CEO is Dr Shivali Gulab, a former NZBIO Young Bioscientist of the Year who is based in New York and driving the progress of Ferrier’s vaccine technology towards human clinical trials. Ferrier Research Institute has had a 20-year working relationship with the Albert Einstein College of Medicine in New York, which has resulted in successful drug trials, including current trials in leukaemia and lymphoma.

“Our vision is zero deaths from breast cancer. That can’t happen without significant investment in game-changing areas, and right now vaccines are top of the list,” said Evangelia Henderson. “We’re so grateful to all our supporters who helped make this programme possible, and who will be as excited as we are about the fantastic work at Ferrier.”

Ferrier Institute director Professor Richard Furneaux says the technology for synthetic cancer vaccines is almost there. “We just need to get it to the next level of testing—human clinical trials.”

Professor Gavin Painter, who leads the chemistry team at Ferrier, says the support of BCFNZ is crucial. “Getting a new therapy to human clinical trials requires significant investment, and an intensive campaign of chemistry, biology and regulatory compliance.


ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Trade Agreements: TPP Minus US Starting To Gain Ground

The Japanese government is picking up the pace on reviving the Trans-Pacific Partnership trade and investment deal, with talks scheduled next month among the 11 countries left in the pact after the withdrawal by the US after the election of president Donald Trump. More>>

ALSO:

PACER:

Prices Up 2.2%: Annual Inflation Highest In Over Five Years

"Rising petrol prices along with the annual rise in cigarette and tobacco tax lifted inflation," prices senior manager Jason Attewell said. "Petrol prices in New Zealand are closely linked to global oil prices, and cigarettes and tobacco taxes rise in the March quarter each year". More>>

ALSO:

Undertaxed? NZ Income Tax Rate Second Lowest Among Developed Nations

New Zealand workers pay the second smallest portion of their income to the government among developed nations and less than half the average ratio of their Organisation for Economic Cooperation and Development peers. More>>

ALSO:

Cyclone Cook: Round Up Of This Week’s Weather

One of the significant impacts this week was flooding due to excessive rainfall amounts. Rainfall amounts topped out at 350mm over the past 60 hours in parts of northwest Nelson, with 200mm+ measurements recorded about Coromandel Peninsula, and between 150-200mm in the Kaimai Ranges. Rainfall amounts of between 30-50mm were commonplace elsewhere. More>>

ALSO:

Earlier: Batten Down The Hatches For Cyclone Cook

Although fast-moving, Cyclone Cook will be destructive and MetService Expert Meteorologists have issued Severe Wind Warnings for the whole of the North Island apart from Northland... More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news